WNT2B与BTRC基因变异预测黑色素瘤生存
基于MD Anderson和哈佛大学两项全基因组关联研究数据,评估151个Wnt通路基因中19,830个常见SNP与皮肤黑色素瘤特异性生存的关联,发现WNT2B rs1175649和BTRC rs61873997两个独立SNP与生存显著相关,可能作为预后生物标志物。
要点
- WNT2B rs1175649 G>T与黑色素瘤特异性生存风险升高相关,校正HR为1.99。
- BTRC rs61873997 G>A与黑色素瘤特异性生存风险降低相关,校正HR为0.61。
- 这两个Wnt通路基因变异需更大规模研究验证后方可用于临床预后评估。
核心结论
- Wnt通路基因WNT2B和BTRC的两个独立SNP与皮肤黑色素瘤特异性生存显著相关,可能作为预后生物标志物。
研究设计与样本
- 利用MD Anderson癌症中心已发表的全基因组关联研究数据,评估151个Wnt通路常染色体基因中19,830个常见SNP与黑色素瘤特异性生存的关联,并在哈佛大学另一项全基因组关联研究中进行验证。
主要发现
- 单位点分析中1,855个SNP在P<0.05水平与黑色素瘤特异性生存显著相关,其中547个经假阳性报告概率校正后仍值得关注。
- 验证阶段经多重比较校正后,两个SNP仍与黑色素瘤特异性生存显著相关。
- 通过功能预测和逐步选择,识别出两个独立SNP:WNT2B rs1175649 G>T和BTRC rs61873997 G>A。
- WNT2B rs1175649 G>T的效应等位基因归因风险比(校正风险比)为1.99(95%CI=1.41-2.81,P=8.10×10^-5)。
- BTRC rs61873997 G>A的效应等位基因归因风险比(校正风险比)为0.61(95%CI=0.46-0.80,P=3.12×10^-4)。
关键数值与推荐
- WNT2B rs1175649 G>T:校正风险比1.99(95%CI=1.41-2.81,P=8.10×10^-5)。
- BTRC rs61873997 G>A:校正风险比0.61(95%CI=0.46-0.80,P=3.12×10^-4)。
临床怎么用
- 这两个Wnt通路基因变异可能作为黑色素瘤患者预后评估的候选生物标志物,但需更大规模研究验证后方可临床应用。
局限性
- 研究基于两项全基因组关联研究数据的再分析,结论需更大规模研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cutaneous melanoma (CM) is the most lethal skin cancer. The Wnt pathway has an impact on development, invasion, and metastasis of CM, thus likely affecting CM prognosis. Using data from a published genome-wide association study from The University of Texas MD Anderson Cancer Center, we assessed the associations of 19,830 common single-nucleotide polymorphisms (SNPs) in 151 Wnt pathway autosomal genes with CM-specific survival and then validated significant SNPs in another genome-wide association study from Harvard University. In the single-locus analysis, 1,855 SNPs were significantly associated with CM-specific survival at P < 0.05, of which 547 SNPs were still considered noteworthy after the correction by the false-positive report probability. In the replication, two SNPs remained significantly associated with CM-specific survival after multiple comparison correction. By performing functional prediction and stepwise selection, we identified two independent SNPs (i.e., WNT2B rs1175649 G>T and BTRC rs61873997 G>A) that showed a predictive role in CM-specific survival, with an effect-allele-attributed hazards ratio (adjusted hazards ratio) of 1.99 (95% confidence interval = 1.41-2.81, P = 8.10 × 10-5) and 0.61 (0.46-0.80, 3.12×10-4), respectively. Collectively, these variants in the Wnt pathway genes may be biomarkers for outcomes of patients with CM, if validated by larger studies.
引用
- Shi Q, Liu H, Han P, et al. Genetic Variants in WNT2B and BTRC Predict Melanoma Survival. J Invest Dermatol. 2017. PMID: 28499756. doi:10.1016/j.jid.2017.04.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。